Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus and Irinotecan in KRAS Mutated mCRC
NCT00827684Phase 2Completed
- Sponsor
- Vejle Hospital
- Start
- Mar 2009
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of temsirolimus in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Vejle Hospital. Primary endpoint: Objective Response Rate. Started Mar 2009; status: completed.
02
Drugs
temsirolimus
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00827684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00827684.